WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced that Frank McGillin, Senior Vice President and General Manger, Consumer, will participate in a panel discussion on the THE DIGITAL HEALTHCARE REVOLUTION at the Wearable Technology Show in Santa Clara, CA on October 5th. Mr. McGillin joins other industry leaders on the panel including Mark Prince, VP Consumer, Withings; Christine Lemke, Co-Founder & President, Evidation Health; and Manish Shah, CEO & Co-Founder, PeerWell.
“Connected health is one of the most exciting growth areas for wearable tech,” said Frank McGillin. “Innovations like Quell® can make a meaningful difference in peoples’ lives, helping them to better manage chronic conditions through a combination of therapy and feedback.”
About Wearable Technology Show USA
The Wearable Technology Show USA is the largest business and prosumer show featuring cutting edge technology under one roof. It is the biggest and best forum for forming partnerships and developing new business across the wearable, smart device and IOT landscape. Over 3,000 delegates, 100 speakers plus press will come together to exchange views, network and do business. The show floor will feature cutting edge technology attracting prosumers, distributors and buyers.
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can start, stop, and adjust therapy discreetly via the optional Quell Relief app. Quell also offers advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
Last updated on: 29/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.